CN111848610B - X crystal form of pyridine derivative, and preparation method and application thereof - Google Patents
X crystal form of pyridine derivative, and preparation method and application thereof Download PDFInfo
- Publication number
- CN111848610B CN111848610B CN202010741115.1A CN202010741115A CN111848610B CN 111848610 B CN111848610 B CN 111848610B CN 202010741115 A CN202010741115 A CN 202010741115A CN 111848610 B CN111848610 B CN 111848610B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- crystal form
- preparation
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention discloses an X crystal form of a pyridine derivative, a preparation method and application thereof, relates to the field of pharmaceutical chemical synthesis, and particularly relates to an X crystal form of a compound 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxo-tetrahydropyrrole-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide compound, a preparation method thereof, and application thereof as a therapeutic drug, in particular to application thereof in preparing a drug for preventing or treating thrombosis or embolism.
Description
Technical Field
The invention relates to the field of pharmaceutical chemistry synthesis, in particular to a polymorphism of a compound 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxo-tetrahydropyrrole-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide compound, a preparation method thereof and application thereof as a therapeutic drug, especially application thereof in preparing a drug for preventing or treating thrombosis or embolism.
Background
Thrombotic diseases are diseases that seriously harm human health, and are mainly classified into arterial thrombosis and venous thrombosis according to the part, condition and nature of thrombosis. Arterial thrombosis is initiated by atherosclerotic lesions and platelet activation of arterial vessel wall, and the severe clinical reactions caused by the arterial thrombosis are mainly acute myocardial infarction and cerebral apoplexy; venous thrombosis is induced by a variety of causes in the venous vasculature, which can lead to Venous Thromboembolism (VTE), which is clinically manifested primarily as Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE). VTE is the third major cardiovascular disease following acute coronary syndrome and stroke. In hospital, the VTE accounts for about 10%, the total number of symptoms VTE in European Union 6 countries is 100 ten thousand per year, and the number of death cases exceeds the sum of deaths caused by AIDS, breast cancer, prostate cancer and traffic accidents. The U.S. death cases exceed 29.6 ten thousand per year, while less than 50% of lethal PE is diagnosed before death. International guidelines have listed VTE prevention as one of the most important strategies for reducing mortality in hospitalized patients.
Evidence from large-scale clinical trials suggests that anticoagulant therapy can prevent the spread and recurrence of thrombi and further reduce the incidence and mortality of stroke, PE, etc. Therefore, anticoagulant therapy has become the core and the foundation of clinical prevention and treatment of thromboembolic diseases at present, and the development of anticoagulant drugs is always a hot spot of new drug development, especially the development of drugs taking Xa factor inhibitor as a target.
The present inventors have surprisingly obtained, through experimental trials during the course of their ongoing research, a novel polymorphic form of a 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxotetrahydropyrrole-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide compound. It is well known that for a polymorphic form of a drug, different crystalline forms may have different chemical and physical properties, including chemical stability, solubility, optical and mechanical properties, etc., which may directly affect the handling and production processes of the drug substance and the formulation, and may affect the stability, solubility and bioavailability of the formulation, and thus, research on the polymorphic form is of great significance to the quality, safety and effectiveness of the drug formulation. For the factor Xa inhibitor, the art has the polymorphic form of the 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxotetrahydropyrrole-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide compound which is more suitable for industrial production and has excellent physicochemical properties.
Disclosure of Invention
The invention discloses a polymorphic crystal form of a 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxo-tetrahydropyrrole-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-formamide compound shown as a structural formula I, a preparation method of each crystal form, and application of each crystal form in preparation of medicines for treating Xa factor inhibitor related diseases. More specifically, the application is the application in the preparation of medicines for preventing or treating thrombus or embolism.
The polymorphic crystal forms of the compound with the structure shown in the formula I specifically comprise crystal forms B, M1, O, P, Q, T, U, V and X.
The present invention provides crystalline form B of the compound of formula I, having a pattern with diffraction angles, interplanar spacings and relative intensities as shown in the following table, as determined by X-ray powder measurements using Cu-ka radiation:
the error of the 2 θ diffraction angle was ± 0.2.
Further, the spectrum of form B has diffraction angles, interplanar spacings and relative intensities shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
Further, form B has an X-ray powder diffraction pattern substantially as shown in figure 2.
The invention provides a crystalline form M1 of the compound of formula I, having the diffraction angles, interplanar spacings and relative intensities shown in the following table, as determined by X-ray powder measurements using Cu-ka radiation:
the error of the 2 θ diffraction angle was ± 0.2.
Further, the spectrum of form M1 has diffraction angles, interplanar spacings and relative intensities as shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
Further, form M1 has an X-ray powder diffraction pattern substantially as shown in figure 3.
In a further aspect the present invention provides crystalline form O of the compound of formula I, having a pattern, as determined by X-ray powder using Cu-ka radiation, having diffraction angles, interplanar spacings and relative intensities as shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
Further, the spectrum of form O has diffraction angles, interplanar spacings and relative intensities shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
Further, form O has an X-ray powder diffraction pattern substantially as shown in figure 4.
In a further aspect the present invention provides crystalline form P of the compound of formula I, having a pattern, as determined by X-ray powder using Cu-ka radiation, having diffraction angles, interplanar spacings and relative intensities as shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
Further, the spectrum of form P has diffraction angles, interplanar spacings and relative intensities shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
Further, form P has an X-ray powder diffraction pattern substantially as shown in figure 5.
In a further aspect the present invention provides crystalline form Q of the compound of formula I, as determined by X-ray powder analysis using Cu-ka radiation, having a spectrum with diffraction angles, interplanar spacings and relative intensities as indicated in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
Further, the spectrum of form Q has diffraction angles, interplanar spacings, and relative intensities shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
Further, form Q has an X-ray powder diffraction pattern substantially as shown in figure 6.
In a further aspect the present invention provides crystalline form T of the compound of formula I, having a pattern, as determined by X-ray powder using Cu-ka radiation, having diffraction angles, interplanar spacings and relative intensities as shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
Further, the crystal form T spectrum has diffraction angles, interplanar spacings and relative intensities shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
Further, form T has an X-ray powder diffraction pattern substantially as shown in figure 7.
In a further aspect the present invention provides crystalline form U of the compound of formula I having a pattern, as determined by X-ray powder using Cu-ka radiation, having diffraction angles, interplanar spacings and relative intensities as shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
Further, the spectrum of the crystal form U has diffraction angles, interplanar spacings and relative intensities shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
Further, form U has an X-ray powder diffraction pattern substantially as shown in figure 8.
In a further aspect the present invention provides a crystalline form V of the compound of formula I having a pattern, as determined by X-ray powder using Cu-ka radiation, having diffraction angles, interplanar spacings and relative intensities as shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
Further, the spectrum of form V has diffraction angles, interplanar spacings and relative intensities shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
Further, form V has an X-ray powder diffraction pattern substantially as shown in figure 9.
In a further aspect the present invention provides a compound of formula I in crystalline form X having a pattern, as determined by X-ray powder using Cu-ka radiation, having diffraction angles, interplanar spacings and relative intensities as shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
Further, the crystal form X spectrum has diffraction angles, interplanar spacings and relative intensities shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
Further, form X has an X-ray powder diffraction pattern substantially as shown in figure 10.
The invention also discloses a polymorphism of the compound with the structure shown in the formula I, which specifically comprises C, D, F, H, I, J, L, M, R and S.
In a further aspect of the invention there is provided crystalline form C of the compound of formula I having a pattern, as determined by X-ray powder using Cu-ka radiation, having diffraction angles, interplanar spacings and relative intensities as shown in the table below.
The error of the 2 θ diffraction angle was ± 0.2.
In a further aspect the present invention provides crystalline form D of the compound of formula I, having a pattern, as determined by X-ray powder using Cu-ka radiation, having diffraction angles, interplanar spacings and relative intensities as shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
In a further aspect the present invention provides crystalline form F of the compound of formula I, having a pattern, as determined by X-ray powder using Cu-ka radiation, having diffraction angles, interplanar spacings and relative intensities as shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
In a further aspect the present invention provides crystalline form H of the compound of formula I having a pattern, as determined by X-ray powder using Cu-ka radiation, having diffraction angles, interplanar spacings and relative intensities as shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
In a further aspect the present invention provides crystalline form I of the compound of formula I, having a pattern, as determined by X-ray powder using Cu-ka radiation, having diffraction angles, interplanar spacings and relative intensities as indicated in the table below.
The error of the 2 θ diffraction angle was ± 0.2.
In a further aspect the present invention provides crystalline form J of the compound of formula I having a pattern, as determined by X-ray powder using Cu-ka radiation, having diffraction angles, interplanar spacings and relative intensities as shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
In a further aspect the present invention provides crystalline form L of the compound of formula I, having a pattern, as determined by X-ray powder using Cu-ka radiation, having diffraction angles, interplanar spacings and relative intensities as shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
In a further aspect of the invention there is provided crystalline form M of the compound of formula I having a pattern, as determined by X-ray powder using Cu-ka radiation, having diffraction angles, interplanar spacings and relative intensities as shown in the table below.
The error of the 2 θ diffraction angle was ± 0.2.
In a further aspect the present invention provides crystalline form R of the compound of formula I, having a pattern, as determined by X-ray powder using Cu-ka radiation, having diffraction angles, interplanar spacings and relative intensities as shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
In a further aspect the present invention provides crystalline form S of the compound of formula I, having a pattern, as determined by X-ray powder using Cu-ka radiation, having diffraction angles, interplanar spacings and relative intensities as shown in the following table:
the error of the 2 θ diffraction angle was ± 0.2.
The invention also discloses a preparation method of the compound 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxo-tetrahydropyrrole-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-formamide in the formula I:
under the condition of room temperature (10-25 ℃), starting material 2-methyl-4-nitroaniline reacts with 5-chloro valeryl chloride to generate a compound a, the compound a generates intramolecular cyclization under the alkaline condition to generate a compound b, the compound b generates a compound c under the action of phosphorus pentachloride, the generated compound c further generates a compound d under the action of morpholine, nitro in the compound d is reduced to generate a compound e, the compound e reacts with 4-chlorobutyryl chloride again to generate a compound f, the compound f generates intramolecular cyclization again to generate a compound g, the compound g and [ (4-methoxyphenyl) hydrazino ] ethyl chloroacetate generate a compound h, and the compound h is aminolyzed to obtain the compound of formula I.
The crystalline forms B, M, O, P, Q, T, U, V and X of the compound of formula I1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxotetrahydropyrrole-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide may be prepared by the following method:
(1) Adding a compound shown in a structure of a formula I into a sample bottle, adding a positive solvent, completely dissolving the compound under the condition of room temperature or reflux, directly or dropwise adding a counter solvent, and cooling to room temperature for crystallization;
(2) Carrying out suction filtration, and drying at room temperature or under heating condition under normal pressure or vacuum to obtain different crystal forms; and optionally, adding the crystal form into an anti-solvent to form a suspension, stirring, filtering, and drying to obtain different crystal forms.
Wherein, the positive solvent is that the compound with the structural formula I has better solubility in the solvent, and the positive solvent is specifically selected from one or more of methanol, ethanol, tetrahydrofuran, acetone, N-dimethylformamide, dioxane, dichloromethane and ethyl acetate; preferably one or more of methanol, ethanol, dichloromethane, N-dimethylformamide and ethyl acetate; the anti-solvent is the compound with the structural formula I, which is provided by the invention, has poor solubility in the solvent, and is specifically selected from one or more of water, methyl tert-butyl ether, n-heptane, n-hexane and cyclohexane; preferably one or more of water, methyl tert-butyl ether and n-heptane.
Further, crystalline forms B, M, O, P, Q, T, U, V and X of the compound of formula I of the present invention may be prepared by the following method:
(1) Adding a compound shown in a structure of a formula I into a sample bottle, adding a positive solvent, completely dissolving the compound under the condition of room temperature or reflux, directly or dropwise adding a counter solvent, and cooling to room temperature for crystallization;
(2) And (4) carrying out suction filtration, and drying at room temperature or under heating condition under normal pressure or vacuum to obtain different crystal forms.
Alternatively, further, crystalline forms B, M, O, P, Q, T, U, V and X of the compounds of formula I of the present invention may be prepared by:
(1) Adding a compound shown in a formula I structure into a sample bottle, adding a positive solvent, completely dissolving the compound under the room temperature or reflux condition, directly or dropwise adding an anti-solvent, and cooling to room temperature for crystallization;
(2) And (3) carrying out suction filtration, drying at room temperature or under heating condition under normal pressure or vacuum to obtain different crystal forms, adding the crystal forms into an anti-solvent to form a suspension, and then stirring, carrying out suction filtration and drying to obtain different crystal forms.
According to the invention, solubility tests show that the crystal form B, the crystal form M1, the crystal form O, the crystal form P, the crystal form Q, the crystal form T, the crystal form U, the crystal form V or the crystal form X of the compound shown in the formula I have good solubility; chemical stability investigation tests for 5 days and 10 days show that the crystal form B, the crystal form M1, the crystal form O, the crystal form P, the crystal form Q, the crystal form T, the crystal form U, the crystal form V and the crystal form X of the compound shown in the formula I have excellent chemical stability. Furthermore, physical stability investigation tests for 10 days show that the crystal form has good physical stability. Furthermore, the invention investigates the moisture absorption of the amorphous, crystal form B, crystal form M1, crystal form O, crystal form P, crystal form Q, crystal form T, crystal form U, crystal form V and crystal form X of the compound shown in the formula I under the normal temperature and humidity conditions, and the results show that the crystal form B and the crystal form X of the invention have no moisture absorption, the crystal form M1, the crystal form O, the crystal form P, the crystal form Q, the crystal form T and the crystal form V have slight moisture absorption, and the crystal form U has moisture absorption.
The test on the effect of the APTT of a normal mouse shows that the amorphous and various crystal forms prepared by the invention have the effect of obviously prolonging the APTT value of the mouse and are all obviously superior to the positive medicine apixaban; compared with the amorphous form, the APTT value of the crystal form B of the invention is remarkably increased (P is less than 0.01), and the APTT values of the crystal forms M1 and O, Q, X are remarkably increased (P is less than 0.05); the effects of the crystal form B, the crystal form M1, the crystal form O, the crystal form Q and the crystal form X are relatively better. The crystal forms B, M and O, Q, X of the compound of the formula I prepared by the invention can be used for preparing anticoagulant, thrombus prevention or embolism treatment medicines, and particularly can be used for preparing anticoagulant medicines or Xa factor inhibitor medicines.
Drawings
FIG. 1 amorphous XRPD pattern of a compound of formula I
FIG. 2 XRPD pattern of form B of compound of formula I
FIG. 3 XRPD pattern of crystalline form M1 of compound of formula I
FIG. 4 XRPD pattern of form O of compound of formula I
FIG. 5 XRPD pattern of form P of compound of formula I
FIG. 6 XRPD pattern for form Q of compound of formula I
FIG. 7 XRPD pattern for form T of compound of formula I
FIG. 8 XRPD pattern of form U of compound of formula I
FIG. 9 XRPD pattern for form V of compound of formula I
FIG. 10 XRPD pattern for form X of compound of formula I
Detailed Description
The present invention will be described in further detail with reference to examples, which are provided only for illustrating the technical solutions of the present invention and are not intended to limit the spirit and scope of the present invention.
The structure of the compound is determined by nuclear magnetic resonance 1 H NMR). Nuclear magnetic resonance ( 1 H NMR) shifts (δ) are given in parts per million (ppm); nuclear magnetic resonance (A) 1 H NMR) was performed using a BrukeraVANCE-400 nuclear magnetic spectrometer using hexadeutero-dimethyl sulfoxide (CDCl) 3 ) Internal standard is Tetramethylsilane (TMS).
Mass Spectrometry (MS) measurements were carried out using a FINNIGAN LCQAD (ESI) mass spectrometer (manufacturer: therm, model: finnigan LCQ advantage MAX).
The HPLC spectra were determined using an Agilent model 1260DAD, agilent, ach.
The term "nitrogen atmosphere" in the present invention means, for example, a reaction flask connected to a 1L volume of nitrogen balloon.
The thin silica gel layer is prepared from HSGF254 or GF254 silica gel plate.
The X-ray powder diffraction (XRPD) was determined by the use of a Panalytical Empyrean X-ray powder diffraction analysis
The specific parameters are shown in the following table:
thermogravimetric analysis (TGA) and Differential Scanning Calorimeter (DSC) data were collected on a TA Q500 thermogravimetric analysis and a TA Q200 differential scanning calorimeter, respectively, and the instrument parameters are listed in the following table:
the term "room temperature" in the present invention means a temperature between 10 ℃ and 25 ℃.
EXAMPLE 1 preparation of the Compound 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxotetrahydropyrrol-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide
The preparation scheme is shown as the following formula:
the first step is as follows: preparation of a
2-methyl-4-nitroaniline (3g, 19.7mmol) was dissolved in dichloromethane (60 ml), N-diisopropylethylamine (6.4 g, 49.5mmol) was added, the temperature was reduced to 5 ℃ or less in an ice bath, 5-chloroacetyl chloride (3.7g, 23.9mmol) was added dropwise to give a reaction mixture, and the reaction mixture was allowed to react at room temperature overnight. The reaction progress was followed by thin layer chromatography, and after completion of the reaction, water was poured into the reaction solution, separated, washed with water 3 times, dried over anhydrous magnesium sulfate, filtered, and the solvent was distilled off under reduced pressure to obtain compound a (4.2 g, yellow solid) in yield: 78.8 percent.
MS m/z(ES):271.1[M+1]
The second step is that: b preparation of
A (4.2g, 15.5 mmol) was dissolved in tetrahydrofuran (80 ml), and sodium hydride (0.75g, 31.3 mmol) was added in portions under ice bath to give a reaction mixture, which was allowed to react at room temperature overnight. The reaction progress was followed by thin layer chromatography, after completion of the reaction, ice water was added to the reaction mixture in ice bath to quench sodium hydride, tetrahydrofuran was removed by distillation under reduced pressure, ethyl acetate was extracted 2 times, dried over anhydrous magnesium sulfate, filtered, and the solvent was removed by distillation under reduced pressure, and the residue was purified by column chromatography to give b (3.27 g, yellow solid), yield: 90.1 percent.
MS m/z(ES)：235.1[M+1]
The third step: c preparation of
B (3.27g, 14.0mmol) was dissolved in methylene chloride (100 ml), and phosphorus pentachloride (8.7g, 41.8mmol) was added in portions under ice bath to give a reaction mixture, which was reacted at 40 ℃ under reflux. When the reaction solution does not generate bubbles basically, the thin layer chromatography tracks the reaction process, after the reaction is completed, ice water is added into the reaction mixture under ice bath to quench phosphorus pentachloride, liquid separation and washing are carried out for 3 times, anhydrous magnesium sulfate is dried, filtration and reduced pressure distillation are carried out to remove the solvent, and then c (4 g, yellow solid) is obtained, and the yield is as follows: 94.6 percent.
MS m/z(ES)：303.0，305.0[M+1]
The fourth step: preparation of d
Dissolving c (4 g, 13.2mmol) in morpholine (40 ml) to obtain a reaction mixture, refluxing the reaction mixture at 120 ℃ for 2 hours, following the progress of the reaction by thin layer chromatography, after completion of the reaction, adding ethyl acetate to dissolve, washing with water 3 times, drying over anhydrous magnesium sulfate, filtering, and distilling off the solvent under reduced pressure to obtain d (3.98 g, black solid), yield: 95.0 percent.
MS m/z(ES)：318.1[M+1]
The fifth step: preparation of e
D (3.98g, 12.5 mmol) was dissolved in ethanol (50 ml), sodium sulfide nonahydrate (9g, 37.5 mmol) was added, and water (20 ml) was further added to obtain a reaction mixture, which was reacted at 50 ℃ under reflux overnight. The reaction progress is tracked by thin layer chromatography, after the reaction is completed, ethanol is removed by concentration under reduced pressure, ethyl acetate is extracted for three times, organic phases are combined, anhydrous magnesium sulfate is dried, filtration is carried out, the solvent is removed by distillation under reduced pressure, and then e (3.2 g, yellow solid) is obtained, and the yield: 88.9 percent.
MS m/z(ES)：288.2[M+1]
And a sixth step: preparation of f
E (3.2 g,11.1 mmol) was dissolved in dichloromethane (50 ml), N-diisopropylethylamine (3.6 g,27.9 mmol) was added, and 4-chlorobutyryl chloride (2.4 g,17.0 mmol) was added dropwise under ice bath to give a reaction mixture, which was allowed to react at room temperature overnight. The reaction progress was followed by thin layer chromatography, after completion of the reaction, water was added to the reaction solution, separated, washed 3 times with water, dried over anhydrous magnesium sulfate, filtered, and the solvent was removed by distillation under reduced pressure to give f (3.5 g, yellow solid) in yield: 80.3 percent.
MS m/z(ES)：392.2[M+1]
The seventh step: preparation of g
F (3.5g, 8.9mmol) was dissolved in tetrahydrofuran (50 ml), and sodium hydride (0.6g, 25mmol) was added in portions under ice bath to give a reaction mixture, which was allowed to react at room temperature overnight. Tracking the reaction process by thin-layer chromatography, after the reaction is completed, adding ice water to the reaction solution to quench sodium hydride, removing tetrahydrofuran by reduced pressure distillation, adding dichloromethane to extract for 2 times, combining organic phases, drying with anhydrous magnesium sulfate, filtering, removing the solvent by reduced pressure distillation, and purifying the residue by column chromatography to obtain g (2.59 g, yellow solid), wherein the yield is as follows: 81.7 percent.
MS m/z(ES)：356.2[M+1]
The eighth step: preparation of h
G (280mg, 0.79mmol) was dissolved in toluene (10 ml), ethyl [ (4-methoxyphenyl) hydrazino ] chloroacetate (214mg, 0.83mmol), triethylamine (252mg, 2.5 mmol) were added at room temperature to give a reaction mixture, and the reaction mixture was refluxed at 120 ℃ overnight. The progress of the reaction was followed by thin layer chromatography, and after completion of the reaction, toluene was distilled off under reduced pressure, and after the residue was dissolved by adding methylene chloride (20 ml), trifluoroacetic acid (2 ml) was added at room temperature to give a reaction mixture, which was allowed to react at room temperature overnight. The reaction progress was followed by thin layer chromatography, after completion of the reaction, h (300 mg, yellow solid) was obtained by column chromatography purification, yield: 77.9 percent.
MS m/z(ES)：489.2[M+1]
The ninth step: preparation of compound of structural formula I1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxotetrahydropyrrole-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide
H (300mg, 0.61mmol) was dissolved in methanol (4 ml), and aqueous ammonia (2 ml) was added to give a reaction mixture, which was reacted at 70 ℃ under reflux overnight. The reaction progress was followed by thin layer chromatography and after completion of the reaction, the compound of formula I (208 mg, pale yellow solid) was purified by column chromatography, yield: 73.8 percent.
MS m/z(ES)：460.2[M+1]
1 H NMR(400MHz,CDCl 3 )δ7.51–7.46(m,4H),7.17(d,J＝8.5Hz,1H),6.93(d,J＝8.8Hz,2H), 6.87(br s,1H),5.54(br s,1H),4.09–4.02(m,1H),3.84–3.79(m,6H),3.45–3.32(m,2H),2.60(t,J＝ 8.0Hz,2H),2.26(s,3H),2.19–2.13(m,2H).
The sample obtained by column chromatography was subjected to solid state analysis using X-ray powder diffraction (XRPD) pattern, and as a result, the sample was found to have no distinct characteristic peak in XRPD, so that the sample was judged to be amorphous, see fig. 1. The product obtained by thin layer chromatography was analyzed by XRPD and the sample was found to be still amorphous.
EXAMPLE 2 preparation of form B of the Compound of formula I
100mg of compound 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxopyrrolidin-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide of formula I, prepared according to example 1, was added to a sample bottle, 3ml of methanol was added, after complete dissolution by heating, cooling to room temperature, suction filtration was carried out, the precipitated crystals were collected and dried under vacuum at 150 ℃ to give 82 mg as a pale yellow solid in 82% yield.
The X-ray powder diffraction pattern of the crystal sample is shown in figure 2, and the pattern has characteristic peaks of diffraction angles, interplanar spacings and relative intensities shown in the following table:
the DSC of the crystalline sample has a characteristic absorption peak at about 202 ℃, and TGA shows that the crystalline sample loses 0.25% of its weight when heated to 150 ℃. According to the above results, the crystal form is an anhydrous crystal form, and is defined as crystal form B.
EXAMPLE 3 preparation of crystalline form M1 of the Compound of formula I
30mg of the compound of the formula I1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxotetrahydropyrrolyl-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide of the formula I, prepared according to example 2, in crystalline form B are added to a sample bottle, 0.5ml of acetone are added, the resulting suspension is stirred overnight at room temperature, and the sample obtained after centrifugal separation is dried at room temperature to give 26mg of a pale yellow solid in 86.7% yield.
The X-ray powder diffraction pattern of the crystal sample is shown in figure 3, and the pattern has characteristic peaks of diffraction angles, interplanar spacings and relative intensities shown in the following table:
the DSC of the crystalline sample has characteristic endothermic/exothermic peaks at about 85 ℃, 106 ℃, 144 ℃, 149 ℃, 179 ℃ and 208 ℃, TGA showing that the crystalline sample loses 7.40% of weight when heated to 100 ℃. Of the crystallized sample 1 The HNMR test result shows that the sample contains 0.2% of acetone by mass, and the acetone can be presumed to be the adsorption solvent by combining the TGA data obtained by the heating test. The water content of the crystal sample was determined by KF method to be 7.2%. From the above results, the crystalline form is dihydrate, defined as form M1.
EXAMPLE 4 preparation of crystalline form O of the Compound of formula I
30mg of the compound 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxopyrrolidin-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide of the formula I, prepared according to example 1, were added to a sample bottle, dissolved by adding 1ml of dichloromethane, slowly evaporating at room temperature to precipitate a solid, suction filtration was carried out, the resulting solid was heated to 180 ℃ under nitrogen and then cooled to room temperature to give 25mg of a pale yellow solid with a yield of 83.3%.
The X-ray powder diffraction pattern of the crystal sample is shown in figure 4, and the pattern has characteristic peaks of diffraction angles, interplanar spacings and relative intensities shown in the following table:
the DSC of the crystalline sample had overlapping endothermic peaks at about 199 ℃ and 208 ℃, and TGA showed a weight loss of 0.82% of the crystalline sample when heated to 180 ℃. According to the above results, the crystal form is an anhydrous crystal form and is defined as crystal form O.
EXAMPLE 5 preparation of crystalline form P of the Compound of formula I
30mg of the compound 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxopyrrolidin-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide of the formula I, prepared according to example 1, were added to a sample bottle, dissolved by adding 1ml of dichloromethane, slowly evaporating at room temperature to precipitate a solid, suction filtration was carried out, the resulting solid was heated to 205 ℃ under nitrogen and then cooled to room temperature to give 24mg of a pale yellow solid with a yield of 80.0%.
The X-ray powder diffraction pattern of the crystal sample is shown in figure 5, and the pattern has characteristic peaks of diffraction angles, interplanar spacings and relative intensities shown in the following table:
the DSC of the crystalline sample has a characteristic absorption peak at about 211 ℃, and TGA shows that the crystalline sample loses 0.24% of weight when heated to 200 ℃. According to the above results, the crystal form is an anhydrous crystal form and is defined as crystal form P.
EXAMPLE 6 preparation of form Q of the Compound of formula I
30mg of the compound 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxopyrrolidin-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide of the formula I, prepared according to example 1, were added to a sample bottle, dissolved by adding 1ml of dichloromethane, slowly evaporating at room temperature to precipitate a solid, suction filtration was carried out, the resulting solid was heated to 140 ℃ under nitrogen and then cooled to room temperature to give 26mg of a pale yellow solid with a yield of 86.7%.
The X-ray powder diffraction pattern of the crystal sample is shown in figure 6, and the pattern has characteristic peaks of diffraction angles, interplanar spacings and relative intensities shown in the following table:
the DSC of the crystalline sample has multiple endothermic/exothermic peaks at about 156 ℃, 168 ℃, 189 ℃, 200 ℃ and 208 ℃, and TGA shows that the crystalline sample loses 1.1% of weight when heated to 150 ℃. According to the above results, the crystal form is an anhydrous crystal form and is defined as crystal form Q.
EXAMPLE 7 preparation of crystalline form T of the Compound of formula I
30mg of the compound 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxotetrahydropyrrol-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide compound of the formula I, prepared according to example 1, are added to a sample bottle, 0.5ml of tetrahydrofuran are added, the resulting suspension is stirred overnight at 50 ℃ and, after centrifugation, dried in vacuo at room temperature. The resulting solid was dissolved in 1.5ml pure water and the resulting suspension was stirred at 50 ℃ overnight and after centrifugation dried under vacuum at room temperature to give 22mg of a pale yellow solid in 73.3% yield.
The X-ray powder diffraction pattern of the crystal sample is shown in figure 7, and the pattern has characteristic peaks of diffraction angles, interplanar spacings and relative intensities shown in the following table:
the DSC of the crystalline sample has a number of characteristic endothermic/exothermic peaks at about 83 ℃, 107 ℃, 148 ℃ and 208 ℃, TGA showing that the crystalline sample loses 7.7% weight when heated to 120 ℃. Of the crystallized sample 1 The HNMR test result shows that the sample contains tetrahydrofuran with the mass fraction of 0.3 percent. The moisture content of the crystal sample was measured by KF method to find that the moisture content was 7.3%. From the above results, the crystalline form is dihydrate, defined as form T.
EXAMPLE 8 preparation of form U of the Compound of formula I
After 15mg of crystalline form T of the compound of formula I1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxopyrrolidin-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide prepared according to example 7 was purged under nitrogen for 40min, 13.5mg of a light yellow solid was obtained in 90.0% yield.
The X-ray powder diffraction pattern of the crystal sample is shown in figure 8, and the pattern has characteristic peaks of diffraction angles, interplanar spacings and relative intensities shown in the following table:
the crystal sample can be quickly absorbed with water and transformed into the crystal form T after being exposed in the air again. According to the above results, the crystal form is an anhydrous crystal form, and is defined as crystal form U.
EXAMPLE 9 preparation of form V of the Compound of formula I
30mg of the compound 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxopyrrolidin-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide compound of formula I, prepared according to example 1, are added to a sample vial, dissolved completely by adding 0.9ml of methanol and slowly evaporated at room temperature to precipitate a solid. After centrifugal separation, the solid obtained was heated to 120 ℃ under nitrogen and then cooled to room temperature to give 18mg of a pale yellow solid in a yield of 60.0%.
The X-ray powder diffraction pattern of the crystal sample is shown in figure 9, and the pattern has characteristic peaks of diffraction angles, interplanar spacings and relative intensities shown in the following table:
the DSC of the crystalline sample has a number of characteristic endothermic/exothermic peaks at about 168 ℃, 175 ℃ and 208 ℃, and TGA shows that the crystalline sample loses 1.9% of weight when heated to 15 ℃. Of the crystalline sample 1 The HNMR test result shows that the mass fraction of methanol contained in the sample is 0.2 percent. K for the crystal sampleThe moisture content of the water-soluble resin was 2.1% by the method F. From the above results, the crystal form is a hydrate crystal form, and is defined as form V.
EXAMPLE 10 preparation of form X of the Compound of formula I
200mg of 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxopyrrolidin-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide, a compound of formula I prepared according to example 1, were added to a sample bottle, 1.6ml of N, N-dimethylformamide was added, after heating to 80 ℃ to completely dissolve it, 1.2ml of water was added dropwise, naturally cooled to room temperature, suction filtered, the precipitated crystals were collected and dried at 70 ℃ to give 166mg of a pale yellow solid with a yield of 83.0%.
The X-ray powder diffraction pattern of the crystal sample is shown in figure 10, and the pattern has characteristic peaks of diffraction angles, interplanar spacings and relative intensities shown in the following table:
the DSC of the crystalline sample has a characteristic absorption peak at about 214 ℃, and TGA shows that the crystalline sample loses 0.32% of weight when heated to 150 ℃. According to the above results, the crystal form is an anhydrous crystal form, and is defined as crystal form X.
EXAMPLE 11 preparation of form B of the Compound of formula I
100mg of the compound 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxotetrahydropyrrol-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide of the formula I, prepared according to example 1, are added to a sample vial, 10ml of ethyl acetate are added, after complete dissolution by heating, cooling to room temperature and suction filtration are carried out, the precipitated crystals are collected and dried in vacuo at 150 ℃ to yield 86mg of a pale yellow solid in 86% yield.
The powder diffraction pattern remained consistent with example 2.
EXAMPLE 12 preparation of crystalline form M1 of the Compound of formula I
50mg of the compound of the formula I1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxotetrahydropyrrolyl-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide, prepared according to example 2, in crystalline form B are added to a sample vial, 0.45ml of tetrahydrofuran are added, the resulting suspension is stirred overnight at room temperature, the sample obtained after centrifugation is dried at room temperature to give 42mg of a pale yellow solid in 84% yield.
The powder diffraction pattern remained consistent with example 3.
EXAMPLE 13 preparation of crystalline form O of the Compound of formula I
40mg of 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxopyrrolidin-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide, the compound of formula I prepared according to example 1, was added to a sample bottle, 0.5ml of tetrahydrofuran and 0.6ml of ethyl acetate were added to dissolve it, solid was precipitated by slow evaporation at room temperature, suction filtration was performed, the resulting solid was heated to 180 ℃ under nitrogen protection and then cooled to room temperature to obtain 34mg of a pale yellow solid, yield 85%.
The powder diffraction pattern remained consistent with example 4.
EXAMPLE 14 preparation of crystalline form P of the Compound of formula I
40mg of the compound 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxotetrahydropyrrol-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide of the formula I, prepared according to example 1, are added to a sample vial, 0.5ml tetrahydrofuran and 0.6ml of ethyl acetate are added and dissolved, slowly evaporated at room temperature to give a solid which precipitates, filtered with suction, the solid obtained is heated to 205 ℃ under nitrogen and then cooled to room temperature to give 28mg of a pale yellow solid in a yield of 70%.
The powder diffraction pattern remained consistent with example 5.
EXAMPLE 15 preparation of crystalline form Q of the Compound of formula I
40mg of 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxopyrrolidin-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide, a compound of the formula I prepared according to example 1, were added to a sample bottle, 0.5ml of tetrahydrofuran and 0.6ml of ethyl acetate were added to dissolve it, the solid precipitated by slow evaporation at room temperature was filtered off with suction, the resulting solid was heated to 140 ℃ under nitrogen and then cooled to room temperature to give 30mg of a pale yellow solid with a yield of 75%.
The powder diffraction pattern remained consistent with example 6.
EXAMPLE 16 preparation of crystalline form T of the Compound of formula I
30mg of 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxotetrahydropyrrol-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide compound of the formula I, prepared according to example 1, are added to a sample bottle, 0.6ml of acetone is added, the resulting suspension is stirred overnight at 50 ℃ and after centrifugation is dried in vacuo at room temperature. The solid obtained is dissolved in 1.5ml of water and the resulting suspension is stirred at 50 ℃ overnight and, after centrifugation, dried under vacuum at room temperature, 24mg of a pale yellow solid are obtained in 80% yield.
The powder diffraction pattern remained consistent with example 7.
EXAMPLE 17 preparation of form U of the Compound of formula I
After 20mg of crystalline form T of the compound of formula I1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxopyrrolidin-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide prepared according to example 16 was purged under nitrogen for 40min, 18.5mg of a light yellow solid was obtained in 92.5% yield.
The powder diffraction pattern remained consistent with example 8.
EXAMPLE 18 preparation of form V of the Compound of formula I
20mg of the compound 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxotetrahydropyrrol-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide compound of the formula I, prepared according to example 1, are added to a sample vial, 0.7ml of dioxane is added and completely dissolved, and slowly evaporated at room temperature to precipitate a solid. After centrifugal separation, the solid was heated to 120 ℃ under nitrogen and then cooled to room temperature to obtain 14mg of a pale yellow solid with a yield of 70.0%.
The powder diffraction pattern remained consistent with example 9.
EXAMPLE 19 preparation of form X of the Compound of formula I
100mg of 1- (4-methoxyphenyl) -7-oxo-6- [ 2-methyl-4- (2-oxopyrrolidin-1-yl) phenyl ] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c ] pyridine-3-carboxamide, a compound of formula I prepared according to example 1, was added to a sample bottle, 0.9ml of N, N-dimethylformamide and 0.5ml of water were added, and after heating to 80 ℃ to completely dissolve it, it was naturally cooled to room temperature, filtered with suction, and the precipitated crystals were collected and dried at 70 ℃ to obtain 73mg of a pale yellow solid with a yield of 73.0%.
The powder diffraction pattern remained consistent with example 10.
Test example 1 solubility test
To examine the solubility of the amorphous form prepared in example 1 of the present invention and the crystalline forms B, M, O, P, Q, T, U, V and X prepared in examples 2 to 10, the present invention measured the equilibrium solubility (saturated solution) of the amorphous form prepared in example 1, the crystalline forms B, M, O, P, Q, T, U, V and X prepared in examples 2 to 10 in hydrochloric acid at pH =1.0 (0.1N) and acetic acid-sodium acetate buffer solution at pH =4.0 at 25 ℃ and 37 ℃ respectively, and the results are shown in table 1 below:
TABLE 1 solubility test
Solubility test results show that the amorphous form, the crystal form B, the crystal form M1, the crystal form O, the crystal form P, the crystal form Q, the crystal form T, the crystal form U, the crystal form V and the crystal form X of the compound shown in the formula I have good equilibrium solubility in hydrochloric acid with the pH =1.0 (0.1N) and acetic acid-sodium acetate buffer solution with the pH =4.0 at the temperature of 25 ℃ and 37 ℃.
Test example 2 chemical stability investigation test
Amorphous form B, M, O, P, Q, T, U, V prepared in example 1 and crystalline form 5363 zxft 3242 prepared in examples 2-10 were placed in a clean petri dish and placed open to the air, stability of the sample was examined under conditions of high temperature (60 ℃), high humidity (25 ℃, RH90% ± 5%), strong light (4500 Lx ± 500 Lx), sampling time was examined for 5 days and 10 days, and placed for 10 days. Samples were taken at 5 days and 10 days, respectively, and the HPLC purity measurements are shown in Table 2 below:
TABLE 2 stability test (% purity)
Stability investigation results show that amorphous form, crystal form B, crystal form M1, crystal form O, crystal form P, crystal form Q, crystal form T, crystal form U, crystal form V and crystal form X shown in the structure of formula I are found through stability comparison under the conditions of high temperature (60 ℃), high humidity (25 ℃, RH90% +/-5%), strong light (4500 Lx +/-500 Lx) and the like under the condition of open placement, and the purity of the crystal form B, the crystal form M1, the crystal form O, the crystal form P, the crystal form Q, the crystal form T, the crystal form U, the crystal form V and the crystal form X has no obvious change under the conditions of high humidity, high temperature and illumination, namely the chemical stability of various crystal forms is better; the purity of the amorphous product under high-humidity conditions is not obviously changed, but the purity of the amorphous product under high-temperature conditions and illumination conditions is obviously reduced. It is demonstrated that the stability of the crystal forms B, M, O, P, Q, T, U, V and X prepared in the embodiments 2 to 10 of the present invention is obviously superior to that of the amorphous form under the conditions of illumination, high temperature and high humidity.
Test example 3 physical stability test
Sample form B prepared in example 2 (as form B0 day reference data, lot number 20140408), sample form P prepared in example 5 (as form P0 day reference data, lot number 20140415), sample form Q prepared in example 6 (as form Q0 day reference data, lot number 20140418), sample form T prepared in example 7 (as form T0 day reference data, lot number 20140421), sample form X prepared in example 10 (as form X0 day reference data, lot number 20140427) were placed in a clean petri dish open and spread, respectively, and physical stability of each crystal form sample was examined under conditions of high temperature (60 ℃), high humidity (25 ℃, RH90% ± 5%), high light (4500 Lx ± 500 Lx), with a sampling time of 10 days. Samples were taken on day 10 and analyzed by solid state X-ray powder diffraction (XRPD) analysis, with the powder diffraction data results shown in tables 3-7 below. The result shows that under the condition of open placement and under the conditions of high temperature, high humidity, strong light and the like, after 10 days, the X-ray powder diffraction angle value (expressed by 2 theta diffraction angle) of the crystal form B, P, Q, T, X is consistent with the reference data of a sample crystal form B, P, Q, T, X for days, namely the crystal form has good physical stability.
TABLE 3 powder diffraction Angle data (2 θ diffraction Angle) of form B under high temperature, high humidity, and light conditions
| PeakNo. | Form B for 0 days | High temperature for 10 days | Illuminating for 10 days | High humidity for 10 days |
| 1 | 10.898560 | 10.864932 | 10.826784 | 10.925483 |
| 2 | 12.203450 | 12.245896 | 12.168134 | 12.195742 |
| 3 | 12.500340 | 12.548621 | 12.526891 | 12.468519 |
| 4 | 14.091510 | 14.126846 | 14.094512 | 14.125623 |
| 5 | 15.742240 | 15.734682 | 15.748952 | 15.786221 |
| 6 | 15.801950 | 15.845612 | 15.795682 | 15.846618 |
| 7 | 22.703550 | 22.711326 | 22.691441 | 22.751343 |
| 8 | 25.202620 | 25.264521 | 25.231568 | 22.215495 |
| 9 | 26.122310 | 26.154313 | 26.118963 | 26.186513 |
Table 4 powder diffraction angle data (2 θ diffraction angle) of form P under high temperature, high humidity, and light conditions
| PeakNo. | Crystal form P0 day | High temperature for 10 days | Illuminating for 10 days | High humidity for 10 days |
| 1 | 6.601970 | 6.654891 | 6.625926 | 6.574135 |
| 2 | 8.155473 | 8.216963 | 8.135899 | 8.152156 |
| 3 | 10.870700 | 10.826325 | 10.921263 | 10.895623 |
| 4 | 11.885930 | 11.841358 | 11.931625 | 11.862592 |
| 5 | 12.954900 | 12.892692 | 12.931592 | 13.024856 |
| 6 | 14.975110 | 14.945862 | 14.982356 | 15.025889 |
| 7 | 15.581570 | 15.558268 | 15.623893 | 15.581662 |
| 8 | 20.268180 | 20.316932 | 20.245811 | 20.285583 |
| 9 | 23.829680 | 23.871669 | 23.794946 | 23.861449 |
TABLE 5 powder diffraction Angle data (2 θ diffraction Angle) of form Q under high temperature, high humidity, and light conditions
Table 6 powder diffraction angle data (2 θ diffraction angle) of form T under high temperature, high humidity, and light conditions
| Peak No. | Crystal form T0 day | High temperature for 10 days | Illuminating for 10 days | High humidity for 10 days |
| 1 | 11.288110 | 11.325896 | 11.315859 | 11.294583 |
| 2 | 11.833850 | 11.824893 | 11.792661 | 11.814692 |
| 3 | 15.940380 | 15.981456 | 15.954826 | 15.895492 |
| 4 | 16.549990 | 16.574892 | 16.498262 | 16.582262 |
| 5 | 18.911510 | 18.948562 | 18.889262 | 18.894825 |
| 6 | 19.280690 | 19.248613 | 19.315658 | 19.325491 |
| 7 | 19.744570 | 19.781561 | 19.714592 | 19.754816 |
| 8 | 21.793840 | 21.845912 | 21.831491 | 21.768911 |
| 9 | 23.679410 | 23.681613 | 23.721464 | 23.644513 |
TABLE 7 powder diffraction Angle data (2 θ diffraction Angle) of form X under high temperature, high humidity, and light conditions
| Peak No. | Crystal form X0 day | High temperature for 10 days | Illuminating for 10 days | High humidity for 10 days |
| 1 | 12.763300 | 12.814492 | 12.784569 | 12.724561 |
| 2 | 14.703580 | 14.745659 | 14.684912 | 14.658922 |
| 3 | 15.083280 | 15.048916 | 15.078916 | 15.125912 |
| 4 | 15.235710 | 15.194823 | 15.214933 | 15.271652 |
| 5 | 18.271200 | 18.241658 | 18.268912 | 18.294816 |
| 6 | 20.528030 | 20.548916 | 20.531813 | 20.498165 |
| 7 | 21.667030 | 21.648913 | 21.694613 | 21.671492 |
| 8 | 22.150960 | 22.134686 | 22.214962 | 22.198135 |
| 9 | 26.184360 | 26.164981 | 26.178916 | 21.215921 |
Test example 4 moisture absorption test
Amorphous B, M, O, P, Q, T, U, V and X samples prepared in example 1 and crystalline B, M, O, P, Q, T, U, V and X prepared in examples 2 to 10 were placed in a clean petri dish in an open and flat manner, and the mass increase percentage was examined by placing the samples in a normal temperature and humidity condition (25 ℃, RH 50%), and the results are shown in table 8 below:
TABLE 8 hygroscopicity test
Test results show that under the conditions of normal temperature and normal humidity (25 ℃, RH 50%), the mass increase percentage of the crystal form B and the crystal form X of the compound of the formula I is less than 0.2 percent, namely no hygroscopicity exists; the mass increase percentage of the crystal form M1, the crystal form O, the crystal form P, the crystal form Q, the crystal form T and the crystal form V is in the range of 0.2 to 2 percent, namely the crystal form has slight hygroscopicity; the mass increase percentage of the crystal form U is more than 2 percent, namely the crystal form U has hygroscopicity.
Effect examples compounds of formula I and their respective crystalline forms have been tested for the effect on normal mouse APTT for purposes of the test: the effect of the crystalline forms prepared in the examples at the 5mg/kg dose on mouse APTT after administration was investigated.
1. Test materials:
1.1. medicine preparation:
the test drugs are: compound of formula I (amorphous), prepared as in example 1, provided by the synthetic research laboratory of medeton pharmaceutical ltd, light yellow solid, lot No.: 20140309;
positive control drug: apixaban, available from Shanghai Haoyuan chemical science and technology, inc., 99.9% pure, under the accession number HM-038 (u 13-20140427);
the test drugs are: form B, prepared as in example 2, was provided by the synthetic research laboratory of medton incorporated, light yellow solid, lot No.: 20140408;
the test drugs are: form M1, prepared as in example 3, was provided by the synthetic research laboratory of medeton pharmaceutical ltd, a light yellow solid, lot No.: 20140409;
the test drugs are: form O, prepared as in example 4, was provided by the synthetic research laboratory of medton incorporated, light yellow solid, lot No.: 20140414;
the test drugs are: form P, prepared as in example 5, was provided by the synthetic research laboratory of medton incorporated, light yellow solid, lot No.: 20140415;
the test drugs are: form Q, prepared as in example 6, was provided by the synthetic research laboratory of medton incorporated, light yellow solid, lot No.: 20140418;
the test drugs are: form T, prepared as in example 7, was provided by the synthetic research laboratory of medeton pharmaceutical ltd, a light yellow solid, lot No.: 20140421;
the test drugs are: form U, prepared as in example 8, was provided by the synthetic research laboratory of medton incorporated, light yellow solid, lot No.: 20140424;
the test drugs are: form V, prepared as in example 9, was provided by the synthetic research laboratory of medeton pharmaceutical limited as a pale yellow solid, lot No.: 20140425;
the test drugs are: form X, prepared as in example 10, was provided by the synthetic research laboratory of medton incorporated, light yellow solid, lot No.: 20140427;
1.2 test equipment:
a Sysmex CA7000 type full-automatic hemagglutination analyzer;
roche C501 full-automatic biochemical analyzer;
blood collection tubes, surgical scissors, syringes, etc.;
1.3 test animals:
KM mice, weight 22-24g, 120 mice, half male and half female, provided by Woodson Biotech, inc., and production facility license SCXK 2013-24. The animals are bred in animal houses after being purchased, adaptability is observed for at least 3 days, and the animals are used for experiments after being qualified for quarantine.
2.1 grouping:
the mice were grouped according to weight in table 9, 10 mice per group, half males and females, with no statistical difference between groups;
table 9 test groups and dosing regimens
2.2APTT determination: respectively feeding corresponding test drugs (physiological saline is fed to a blank group) to each group of the intragastric administration according to the table 9, taking blood from the orbit in a 0.5ml vacuum blood collection tube containing sodium citrate after 1h of administration, and measuring the APTT of each animal after blood sample collection;
3. the statistical method comprises the following steps:
the Excel is adopted for statistics, and experimental data are adopted
Showing that the comparison between the groups was statistically compared using the two-sided T-test method.
4. And (3) test results:
TABLE 10 Effect on normal mouse APTT
Note: compared to blank group ＊ P＜0.05； ＊＊ P＜0.01；
Compared with the positive group △ P＜0.05； △△ P＜0.01；
Compared with the group of example 1 ◇ P＜0.05； ◇◇ P＜0.01。
5. And (4) conclusion:
(1) As can be seen from table 10, after 1h of administration, the APTT (partial thromboplastin activation time) values of the positive group and the example groups were significantly increased (P < 0.01) compared to the blank group, which indicates that the positive drug apixaban, example 1 and the crystal forms thereof can significantly prolong the APTT value of the mice after 1h of administration;
(2) Compared with the positive group, the APTT value of each example group is remarkably increased (P is less than 0.01), which shows that the compound (amorphous) of example 1 and each crystal form thereof are superior to the positive group in prolonging the APTT value of mice;
(3) The APTT values of the example 2 group were significantly increased (P < 0.01) compared to the example 1 group, while the APTT values of the example 3,4, 6, 10 groups were significantly increased (P < 0.05), indicating that the effects of the crystalline form B of the compound of example 2, the crystalline form M1 of the compound of example 3, the crystalline form O of the compound of example 4, the crystalline form Q of the compound of example 6, and the crystalline form X of the compound of example 10 were relatively better.
It will be apparent to those skilled in the art that various modifications and variations can be made in the compounds, compositions, and methods of making the same of the present invention without departing from the spirit or scope of the invention, and therefore, the scope of the invention encompasses all modifications and variations that fall within the scope of the claims and their equivalents.
Claims (6)
1. A crystalline form X of a compound of formula I, characterized by X-ray powder measurements using Cu-k rays, having the diffraction angles, interplanar spacings and relative intensities shown in the following table:
。
2. a crystalline form X of the compound of claim 1, characterized by an X-ray powder diffraction pattern substantially as shown in figure 10.
3. A process for preparing the compound of formula I of claim 1 in crystalline form X comprising the steps of: adding 200mg of the compound shown in the structural formula I into a sample bottle, adding 1.6ml of N, N-dimethylformamide, heating to 80 ℃ to completely dissolve the compound, dropwise adding 1.2ml water, naturally cooling to room temperature, performing suction filtration, collecting precipitated crystals, and drying at 70 ℃ to obtain 166mg pale yellow solid.
4. Use of crystalline form X of a compound of formula I according to claim 1 for the preparation of a medicament for the prevention or treatment of thrombosis or embolism.
5. Use of crystalline form X of a compound of structural formula I according to claim 1 for the preparation of an anticoagulant medicament.
6. Use of crystalline form X of a compound of structural formula I according to claim 1 for the preparation of a factor Xa inhibitor medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010741115.1A CN111848610B (en) | 2015-12-08 | 2015-12-08 | X crystal form of pyridine derivative, and preparation method and application thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510896986.XA CN106854197B (en) | 2015-12-08 | 2015-12-08 | Polycrystal of pyridine derivative and preparation method and application thereof |
| CN202010741115.1A CN111848610B (en) | 2015-12-08 | 2015-12-08 | X crystal form of pyridine derivative, and preparation method and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510896986.XA Division CN106854197B (en) | 2015-12-08 | 2015-12-08 | Polycrystal of pyridine derivative and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111848610A CN111848610A (en) | 2020-10-30 |
| CN111848610B true CN111848610B (en) | 2022-11-18 |
Family
ID=59132291
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010741117.0A Pending CN111718343A (en) | 2015-12-08 | 2015-12-08 | T crystal form of pyridine derivative, and preparation method and application thereof |
| CN202010741116.6A Pending CN111848611A (en) | 2015-12-08 | 2015-12-08 | Q crystal form of pyridine derivative, and preparation method and application thereof |
| CN201510896986.XA Active CN106854197B (en) | 2015-12-08 | 2015-12-08 | Polycrystal of pyridine derivative and preparation method and application thereof |
| CN202010740681.0A Pending CN111848609A (en) | 2015-12-08 | 2015-12-08 | U crystal form of pyridine derivative, and preparation method and application thereof |
| CN202010741119.XA Pending CN111763203A (en) | 2015-12-08 | 2015-12-08 | O crystal form of pyridine derivative, and preparation method and application thereof |
| CN202010741120.2A Pending CN111704612A (en) | 2015-12-08 | 2015-12-08 | P crystal form of pyridine derivative, and preparation method and application thereof |
| CN202010740640.1A Pending CN111808099A (en) | 2015-12-08 | 2015-12-08 | M1 crystal form of pyridine derivative, and preparation method and application thereof |
| CN202010740677.4A Pending CN111848608A (en) | 2015-12-08 | 2015-12-08 | V crystal form of pyridine derivative, preparation method and application thereof |
| CN202010741115.1A Active CN111848610B (en) | 2015-12-08 | 2015-12-08 | X crystal form of pyridine derivative, and preparation method and application thereof |
Family Applications Before (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010741117.0A Pending CN111718343A (en) | 2015-12-08 | 2015-12-08 | T crystal form of pyridine derivative, and preparation method and application thereof |
| CN202010741116.6A Pending CN111848611A (en) | 2015-12-08 | 2015-12-08 | Q crystal form of pyridine derivative, and preparation method and application thereof |
| CN201510896986.XA Active CN106854197B (en) | 2015-12-08 | 2015-12-08 | Polycrystal of pyridine derivative and preparation method and application thereof |
| CN202010740681.0A Pending CN111848609A (en) | 2015-12-08 | 2015-12-08 | U crystal form of pyridine derivative, and preparation method and application thereof |
| CN202010741119.XA Pending CN111763203A (en) | 2015-12-08 | 2015-12-08 | O crystal form of pyridine derivative, and preparation method and application thereof |
| CN202010741120.2A Pending CN111704612A (en) | 2015-12-08 | 2015-12-08 | P crystal form of pyridine derivative, and preparation method and application thereof |
| CN202010740640.1A Pending CN111808099A (en) | 2015-12-08 | 2015-12-08 | M1 crystal form of pyridine derivative, and preparation method and application thereof |
| CN202010740677.4A Pending CN111848608A (en) | 2015-12-08 | 2015-12-08 | V crystal form of pyridine derivative, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (9) | CN111718343A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104650072A (en) * | 2013-11-18 | 2015-05-27 | 成都苑东药业有限公司 | Pyridine derivatives |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101065378A (en) * | 2004-09-28 | 2007-10-31 | 布里斯托尔-迈尔斯斯奎布公司 | Crystalline forms of a pyrazolo[3,4-c]pyridine factor xa inhibitor |
| ES2559212T3 (en) * | 2010-06-09 | 2016-02-11 | Abbvie Bahamas Ltd. | Crystal forms of kinase inhibitors |
| CN102964349A (en) * | 2011-08-31 | 2013-03-13 | 江苏恒瑞医药股份有限公司 | Tosilate of benzodiazepine derivative, its crystal forms, their preparation method and application |
| WO2013119328A1 (en) * | 2012-02-07 | 2013-08-15 | Assia Chemical Industries Ltd. | Solid state forms of apixaban |
| FR2992314B1 (en) * | 2012-06-22 | 2015-10-16 | Sanofi Sa | NOVEL 2,3-DIHYDRO-1H-IMIDAZO {1,2-A} PYRIMIDIN-5-ONE AND 1,2,3,4-TETRAHYDRO-PYRIMIDO {1,2-A} PYRIMIDIN-6-ONE DERIVATIVES COMPRISING A SUBSTITUTED MORPHOLINE, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE |
| CN103539795A (en) * | 2013-03-18 | 2014-01-29 | 齐鲁制药有限公司 | Apixaban polymorph and preparation method thereof |
| CN104292228B (en) * | 2013-07-16 | 2016-03-30 | 成都苑东生物制药股份有限公司 | Polymorphic of a kind of Xanthine compounds and preparation method thereof, purposes |
| CN103342704B (en) * | 2013-07-25 | 2016-08-17 | 甘肃皓天化学科技有限公司 | A kind of preparation method of antithrombotic reagent Eliquis |
| CN104513239B (en) * | 2014-12-10 | 2017-08-22 | 沈阳药科大学 | The ketone compounds of pyrazolo [3,4 c] pyridine 7 and its application |
-
2015
- 2015-12-08 CN CN202010741117.0A patent/CN111718343A/en active Pending
- 2015-12-08 CN CN202010741116.6A patent/CN111848611A/en active Pending
- 2015-12-08 CN CN201510896986.XA patent/CN106854197B/en active Active
- 2015-12-08 CN CN202010740681.0A patent/CN111848609A/en active Pending
- 2015-12-08 CN CN202010741119.XA patent/CN111763203A/en active Pending
- 2015-12-08 CN CN202010741120.2A patent/CN111704612A/en active Pending
- 2015-12-08 CN CN202010740640.1A patent/CN111808099A/en active Pending
- 2015-12-08 CN CN202010740677.4A patent/CN111848608A/en active Pending
- 2015-12-08 CN CN202010741115.1A patent/CN111848610B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104650072A (en) * | 2013-11-18 | 2015-05-27 | 成都苑东药业有限公司 | Pyridine derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106854197A (en) | 2017-06-16 |
| CN111848611A (en) | 2020-10-30 |
| CN111848609A (en) | 2020-10-30 |
| CN111848610A (en) | 2020-10-30 |
| CN111808099A (en) | 2020-10-23 |
| CN111718343A (en) | 2020-09-29 |
| CN111763203A (en) | 2020-10-13 |
| CN106854197B (en) | 2020-09-01 |
| CN111848608A (en) | 2020-10-30 |
| CN111704612A (en) | 2020-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998058901A1 (en) | 3-anilino-2-cycloalkenone derivates | |
| WO2018181345A1 (en) | Heterocyclic compound | |
| CN104910159A (en) | Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same | |
| CN110590796B (en) | Camptothecin derivative and preparation method and application thereof | |
| CN111094241B (en) | Crystal form of oxopyridine amide derivative and preparation method thereof | |
| CN111848610B (en) | X crystal form of pyridine derivative, and preparation method and application thereof | |
| TW438800B (en) | N-(2-benzothiazolyl)-1-piperidineethanamine derivatives, their preparation and their use in therapy | |
| WO2020173417A1 (en) | Acryloyl-containing nuclear transport regulator and uses thereof | |
| WO2008019572A1 (en) | Meptazinol biligand derivatives and/or their salts, preparation method and uses thereof | |
| JPH0559117B2 (en) | ||
| JP2020189856A (en) | Crystalline form of sofpironium bromide and preparation method thereof | |
| CN107602518B (en) | Coumarin-dithiocarbamate derivative and synthesis method thereof | |
| JP7348214B2 (en) | Crystal forms of HDAC6 selective inhibitors and uses thereof | |
| CN115677698B (en) | High-efficiency antiviral compound and application thereof | |
| CN109422739B (en) | Deuterated indoleamine 2, 3-dioxygenase inhibitor and application thereof | |
| CN114702444B (en) | AHA1 inhibitor with multiple myeloma resistance and preparation method and application thereof | |
| CN109796319B (en) | Synthetic method of isopentenyl chalcone derivative and application of prenyl chalcone derivative in pharmacy | |
| JP2024517608A (en) | Crystalline carbazole derivatives | |
| TW202340167A (en) | Crystal form of sulfur-containing isoindoline derivatives | |
| CN116640124A (en) | Preparation method and application of 4- (7-methoxy-3, 4-dihydroquinoxaline-2 (1H) -ketone-4-yl) coumarin | |
| TW202333694A (en) | Crystal form of fused ring derivative and preparation method and application thereof | |
| CA3138394A1 (en) | Novel compounds | |
| EP4303211A1 (en) | Industrial process for the preparation of hexanoic acid, 6(nitrooxy)-,(1s,2e)-3-[(1r,2r,3s,5r)-2-[(2z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]3,5-dihydroxycyclopentyl]-1-(2-phenyl ethyl)-2-propen-1-yl ester and high pure product | |
| CN116554171A (en) | Novel crystal form, application and preparation method of BRD4 inhibitor compound | |
| CN117003766A (en) | Anti-influenza virus derivative and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |